Normax assembled the mRNA UCV Consortium, founded for the development and delivery of mRNA Vaccines for infectious diseases and cancers. Normax has engaged over 30 leading service providers and preferred vendors – biomedical, engineering, financial, legal, corporate – to help Normax to deliver R&D and manufacturing of safe and effective mRNA Vaccines rapidly and efficiently.
Normax is developing the mRNA UCV Consortium with the mission to develop and manufacture mRNA Vaccines at industrial scale for Advance Purchase Agreements (APA) by sponsors, governments and industry customers. The vision of mRNA UCV Consortium is to develop mRNA Vaccines initially for COVID, TB, HIV and Malaria, and to stimulate and support pandemic preparedness for future outbreaks.
Service Providers • Preferred Vendors • Stakeholders • Supporters • Partners
Service Provider
Service Provider
Preferred Vendor
Service Provider
Service Provider
Preferred Vendor
Service Provider
Service Provider
Service Provider
Preferred Vendor
Service Provider
Service Provider
Service Provider
Service Provider
Service Provider
Service Provider
Service Provider
Service Provider
Membership
Strategic Partner
Service Provider
Service Provider
Preferred Vendor
Service Provider
Preferred Vendor
Strategic Partner
Service Provider
Service Provider
Service Provider
Service Provider
Preferred Vendor
Preferred Vendor
Service Provider
Preferred Vendor
Strategic Partner
Membership
Membership
Service Provider
Service Provider
MRNA Vaccine Platform
The scientific competence and technical experience of the researchers at Normax plan to develop the mRNA Vaccine Platform for open development of new mRNA vaccines by members of the mRNA UCV Consortium, and Vaxcomm – The Vaccine FTO Commons, and to help enable Normax to grow the international export business with the mRNA vaccines and contact manufacturing services for domestic and international customers.
Normax and the mRNA UCV Consortium have started a project collaboration; “Development of a lipid nanoparticle platform for mRNA Formulation”. Normax has established the LNP Formulation for the mRNA Vaccine Platform. The project will develop a novel Lipid Nanoparticle (LNP) Formulation to be used in the mRNA Vaccine Platform.
A technological challenge concerning the mRNA vaccines is the requirement for cold storage and transportation due to stability issues. The goal of the NORMAX-LNP project is the development of a mRNA-LNP platform for mRNA formulation, with potential superiority in terms of stability and shelf-life. The innovation output from this project will result in sustainable value creation as the mRNA-LNP platform will be key for Normax to move towards realization of an mRNA product manufacturing facility, and the development of new and stable mRNA products, including vaccines.
With the help of world class academic research groups related to vaccines and immunology, the mRNA-LNP platform will provide the additional capacity needed to commercialize academic and technology transfer offices (TTO) generated projects. An international benefit of the mRNA-LNP platform is the role it plays in developing stable mRNA products that can be exported to Low- and Medium-Income Countries with minimal storage and transportation challenges. It will enable Normax to grow the international export business with the mRNA products, including vaccines, as well as contract manufacturing services for domestic and international customers.